Old gout drug could help curb alcohol cravings, new trial suggests

NCT ID NCT07118618

Recruiting now Disease control Sponsor: Brown University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether probenecid, a drug currently used for gout, can reduce alcohol cravings and drinking in people with alcohol use disorder. Over 16 weeks, 120 participants will receive either probenecid or a placebo, and researchers will measure changes in craving and alcohol consumption. The goal is to see if this drug offers a new way to help manage alcohol use disorder.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Probenecid (oral tablet, 2 grams daily)
What this could lead to: If it works, this could point toward a new treatment option to help people with alcohol use disorder reduce cravings and drinking.
What could go wrong: This is an early Phase 2 trial with only 120 people, so results may not apply to everyone. Probenecid can cause side effects like kidney issues or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL CONSUMPTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse Alcohol Drinking

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL CONSUMPTION ALCOHOL USE DISORDER (AUD) CRAVING

Contacts and locations

Locations

Brown University
RECRUITING

Providence, Rhode Island, 02903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.